Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD 19/03/2014
A phase 4, multi-centre, three-arm, randomised, open-label [SF1] clinical trial lasting 12 months, to evaluate the efficacy and safety of two treatment systems: the bimonthly or individualised flexible PRN “treat-and-extend” regimen; versus a PRN regimen of intravitreal injections of Ranibizumab 0.5 mg in keeping with stabilisation criteria based on monthly controls [SF2] in antiretroviral-naive patients with choroidal neovascularization secondary to age-related macular degeneration. An IN-EyE study.
If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible.
Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела